Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
CA 2344993 C · Owner: Vadeco Biotech Gmbh & Co. Kg · Inventors: Reimann, Hansjorg; Schirmbeck, Reinhold
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a polynucleotide encoding a fusion protein which is stable in a cell, said fusion protein comprising a first (poly)peptide and a second (poly)peptide which co-precipitates a chaperone. The present invention also relates to a vector comprising the polynucleotide of the invention, a host cell comprising the polynucleotide or the vector of the invention, and a method for the production of the fusion protein of the invention. Also described are methods for the production of said first (poly)peptide, of a fusion protein/chaperone complex and of an antibody , directed against said first (poly)peptide as well as a method of immunizing a , subject with the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 2, 1998 and granted November 13, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 2, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 2, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.